# M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer

> **NCT03579472** · PHASE1 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 38 (actual)

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic Triple-Negative Breast Carcinoma
- Prognostic Stage IV Breast Cancer AJCC v8

## Interventions

- **DRUG:** Bintrafusp Alfa
- **DRUG:** Eribulin Mesylate

## Key facts

- **NCT ID:** NCT03579472
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-30
- **Primary completion:** 2022-09-21
- **Final completion:** 2022-09-21
- **Target enrollment:** 38 (ACTUAL)
- **Why stopped:** Due to the fact that the sponsor decided not to move forward with the development of M7824
- **Last updated:** 2022-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03579472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03579472, "M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT03579472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*